A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician’s Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Daiichi Sankyo Inc
To compare the efficacy of I-DXd with that of TPC, as measured by ORR per BICR and OS, in subjects with relapsed SCLC.
Enrollment Form
This study is currently enrolling.